Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MOC.WAR
- Price
- 6.71
- Stock movement down
- -0.21 (-3.13%)
- Company name
- Molecure S.A.
- Exchange
- (WAR ,
- Currency
- PLN )
- Sector
- Healthcare >Biotechnology
- Market cap
- 133.92M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-10-31
DIVIDENDS
MOC.WAR does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.72 |
| Daily high | 6.86 |
| Daily low | 6.50 |
| Daily Volume | 33K |
| All-time high | 7.84 |
| 1y analyst estimate | 18.25 |
| Beta | 2.27 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| MOC.WAR | S&P500 | |
| Current price drop from All-time high | -14.41% | -1.10% |
| Highest price drop | -17.09% | -19.00% |
| Date of highest drop | 31 Oct 2025 | 8 Apr 2025 |
| Avg drop from high | -3.72% | -2.76% |
| Avg time to new high | 7 days | 5 days |
| Max time to new high | 21 days | 89 days |
COMPANY DETAILS
Marketcap
133.92M
Marketcap category
Small-cap
Description
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
Employees
92
Website
Investor relations
-
SEC filings
CEO
Country
Poland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found